Nicholas Williams is listed as a director on 2 SEC Form D filings by 1 issuer between Jul 2023 and Feb 2026: Altesa BioSciences, Inc. (College Park, GA — pharmaceuticals — 2023–2026; $75M reported sold to 18 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Brett Giroir (2 shared filings), Ittai Harel (2 shared filings), John Clerici (2 shared filings), Moncef Slaoui (2 shared filings), Seth Rudnick (2 shared filings) and 2 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Nicholas. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 3 bankruptcy cases matching the name listed in Key records below.
What this means 3 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 2 public filings for Nicholas Williams and found 3 differences: Offering amount changed between filings; Same name, different state: "NICHOLAS WILLIAMS" (E9 or X0 or C0) is a separate record; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.